Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.